Recent advances in cellular immunotherapies are providing new and exciting treatments to fight against difficult-to-treat forms of cancer. These new therapies, such as patient-derived (autologous) Chimeric Antigen Receptor T-cells (CAR-T) and T-Cell Receptors (TCR) also bring with them new challenges for scalable and reproducible commercial production. Due to the nature of autologous cellular immunotherapies, the high variability of incoming patient material requires an increased focus on process analytics, robust and stable single-use consumables, and the implementation of automation to improve process control.
Sartorius provides the cellular immunotherapy industry with a range of scalable single-use production technologies. These tools range from the initial culture media development and supply to viral vector transduction and cellular expansion, on to the downstream processing steps including harvest, wash, and concentration of the cells. Sartorius offers a variety of analytical technologies that allow for the support of the industry’s clinical and commercial production needs. Enhanced characterization of the individual therapy ensures the safety of the cellular immunotherapy products and the control of the production process.
The Biostat® RM TX and Flexsafe® RM TX bag combination provides you with an automated, wave-mixed and closed environment for culturing consistent quality cell products. The cGMP compliant system consists of an automated control unit and a rocking platform and is perfectly suitable for small volume autologous processes with multi-parallel scale out needs. The bioreactor can also be equipped with process analytical technologies (PAT); for example real-time, in-situ measurement of viable biomass with BioPAT® Viamass which allows for highly variable patient material to be monitored during the expansion phase without destructive sampling.
Biostat® RM TXBiostat® RMBioPAT® Viamass
With the ability to multiplex cellular phenotype and function from a mix of cell types in a single well, the iQue Screener PLUS is the ideal solution for delving into the complexities and nuances of the immune system, including changes in signaling molecules, cytokine secretion, and measures of cellular health. By employing sophisticated automation and rapidly sample delivery, the iQue Screener PLUS converts the low throughput, time consuming flow cytometry approach into a truly high throughput method: analyze 96-well plates in less than five minutes and 384-well plates in under 20 minutes. The iQue Screener PLUS can sample as little as 1 µL from each well, allowing assay volumes to be miniaturized down to 9 µl, saving reagent costs and conserving limited patient samples. The powerful purpose-built ForeCyt data analysis and visualization software makes short work of large combinatorial datasets for the fastest time to answer and decision making.
iQUE Screener PLUS
The Microsart® ATMP Mycoplasma kit is a real-time PCR-based technology that allows for fast and easy detection of contaminating mycoplasma species in only 3 hours. Sartorius designed this kit especially to test for mycoplasma contamination in advanced therapy medical products (ATMP), such as cell-based therapeutics. The fast detection time provided by the Microsart® ATMP kits is critical for products with short shelf life, such as cellular immunotherapies. The Microsart® ATMP Mycoplasma kit has been validated according to EP 2.6.7 in combination with EP 2.6.21 with respect to the detection limit for all listed Mycoplasma species.
Microsart® ATMP Mycoplasma
The 4Cell® Nutri-T medium is a xeno-free medium, optimized for the activation and expansion of PBMC's (T cells, CAR-T) and TILs in ex-vivo cell culture conditions. 4Cell® Nutri-T eliminates the need for serum addition, and thus simplifies the process, lowers the regulatory risk, and reduces the associated logistical burden. 4Cell® Nutri-T was developed using actual cancer patient cells, and it shows excellent performance for PBMC, TIL and CAR-T, even at low initial seeding densities.
4Cell® Nutri-T GMP
Automation of CAR-T Cell Adoptive Immunotherapy Bioprocessing: Technology Opportunities to Debottleneck Manufacturing
The Potential Application of Real‑Time Release Testing for the Biomanufacture of Autologous Cell‑Based Immunotherapies
We provide a unique implementation methodology for your bioprocess using SU technologies and hybrid solutions for your type & scale of process.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.